Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical Device Deals Update, March 2016

Executive Summary

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced January-February 2016.

You may also be interested in...



Merit Faces Subpoena Over Marketing

The US Department of Justice is behind the Oct. 19 subpoena, which asks for more information and documents related to Merit’s marketing and promotional practices.

FDA Greenlights Historical Control In Trial Of Regentis' GelrinC Knee Repair Material

The pivotal clinical study will support a US pre-market approval to allow Regentis Biomaterials to market GelrinC for the repair of focal knee cartilage defects in the knee, the largest unmet need in orthopedic sports medicine, according to the company.

Inter Parfums Has ‘Best Year’ In 2021 As Sales Grow 23% Compared With Pre-Pandemic

New York-based fragrance manufacturer and distributor Inter Parfums reports full-year 2021 sales growth of 23% to $879.6m, significantly higher than the $810m projected in October, with successful launches and integration of new fragrance licenses. The NPD Group stated in a 24 January report that fragrance was the best-performing prestige beauty category in the US in 2021, with sales up 49%.

Topics

Related Companies

UsernamePublicRestriction

Register

MT036001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel